The JAK-STAT Pathway in Cancer: Signalling from Cytokines to Genes

The Core Mechanism

Cytokines and some growth factors bind receptors that have no kinase activity of their own but carry associated JAK kinases (JAK1, JAK2, JAK3, TYK2). Ligand binding brings two receptor chains together so the JAKs can transphosphorylate each other and the receptor.

STAT proteins dock on the phosphorylated receptor, are themselves phosphorylated, dimerise, and move to the nucleus to activate specific gene programmes. The pathway is normally switched off within hours by phosphatases, SOCS proteins and PIAS proteins.

Which STAT, Which Outcome

Different cytokines engage different STATs. STAT1 largely mediates interferon responses and can be growth-suppressive and pro-immune; STAT3 and STAT5 more often support proliferation and survival, and STAT3 additionally dampens anti-tumour immunity.

The same pathway can therefore be tumour-suppressive or tumour-promoting depending on which branch is active.

JAK2 and Myeloproliferative Neoplasms

The JAK2 V617F mutation makes the kinase constitutively active and is found in most cases of polycythaemia vera and roughly half of essential thrombocythaemia and primary myelofibrosis. Related mutations affect the thrombopoietin receptor gene MPL and the chaperone gene CALR, all converging on JAK-STAT activation.

Rearrangements that fuse JAK2 to partner genes occur in some leukaemias and lymphomas.

JAK Inhibitors

Ruxolitinib and fedratinib (JAK1/JAK2 inhibitors) are approved for myelofibrosis and polycythaemia vera, where they reduce spleen size and symptoms without eliminating the malignant clone. Other JAK inhibitors are approved for inflammatory diseases and graft-versus-host disease.

In solid tumours, JAK inhibition is being explored mainly in combination, including with immune-checkpoint blockade, based on STAT3-driven immune suppression.

Interpretation Notes

A JAK2 V617F result is reported with its variant allele fraction, which correlates with disease burden, and is interpreted within formal diagnostic criteria for myeloproliferative neoplasms.

In solid-tumour panels, JAK-STAT pathway findings are generally biological context rather than approved treatment-selection markers.

Key Takeaways

• ·JAK-STAT is a direct cytokine-receptor-to-nucleus signalling route.
• ·STAT1 tends to be growth-suppressive and pro-immune; STAT3 and STAT5 tend to promote tumours.
• ·JAK2 V617F drives most myeloproliferative neoplasms; JAK inhibitors control symptoms but not the clone.
• ·In solid tumours, JAK-STAT findings are usually context, not companion diagnostics.